Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of glofitamab plus GemOx in relapsed/refractory DLBCL or MCL (Japan)
jRCT2051250036Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), sponsored by Chugai Pharmaceutical Co., Ltd. Started Aug 2025; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on jRCT2051250036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250036.